Symposium: Opportunities for MIDD for cell therapies

Are you interested in the future of clinical use of cell therapies? Attend the symposium on the 6th of November during ACoP, where Anna Mc Laughlin from Pharmetheus will chair and share her knowledge about 'Opportunities for Model-Informed-Drug-Development (MIDD) for cell therapies'.

Symposium session, November 6, 2.30 – 4.00 PM

Model-based optimization for (CAR-T) Cell Therapies – The current state of affairs and a way forward.

Chaired by

Anna Mc Laughlin, Dr. rer.nat, Consultant. Pharmetheus

Cassian Yee, Professor, University of Texas MD Anderson Cancer Center


Cellular therapy, especially chimeric antigen receptor (CAR)-T cell therapy, has revolutionized the treatment of relapsed/refractory hematological malignancies. Several modeling and simulation (M&S) strategies, using a broad range of methodological approaches, have been developed to support both the rational development and clinical use of CAR-T cell therapy.


This session aims at reflecting on the potential of existing CAR-T cell M&S strategies and highlighting the requirements from different stakeholders (industry, clinical/research, and regulatory) to further establish their use. Finally, as cell therapies beyond CAR-T cells evolve rapidly for oncology and other therapeutic areas, this session aims to provide an outlook on emerging cell therapy concepts and the associated challenges in translating existing CAR-T cell M&S strategies to new therapeutic modalities.

Topics & speakers

Aman P. Singh, Ph.D.
Associate Director, Takeda

Loretta Nastoupil, MD, Associate Professor.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center

Thibaud Derippe, Ph.D.
Clinical Pharmacologist & Pharmacometrician, AstraZeneca

Xiaofei Wang, Ph.D.
Scientist, FDA

Panel discussion